GeoVax Labs rises on COVID vaccine data
24/05/2023 17:42
** Shares of vaccine developer GeoVax Labs Inc GOVX.O rise
12.5% to $0.74
** Co says next-generation COVID-19 vaccine shows high
immunogenicity in immunocompromised patients
** Preliminary analysis indicated CM04S1 is highly
immunogenic in patients undergoing hematological cancer
treatment- GOVX
** CM04S1 is being studied in two mid-stage trials, one as a
primary vaccine for immunocompromised cancer patients, in direct
comparison to either the Pfizer PFE.N or Moderna MRNA.O mRNA
vaccine and second as a booster for healthy patients who have
previously received either as their initial inoculation
** Stock up ~11% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))